Kohei Shitara: Happy to report biomarkers in DESTINIY GC01 at Nature Medicine

Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan shared a post on X:

“Happy to report biomarkers in DESTINIY GC01 at Nature Medicine. Trastuzumab Deruxtecan (T-DXd), response high if ctDNA+ while still activity observed in negative patients. Response regardless of KRAS, HER2, PIK3CA mutation. Decrease response in other RTKamp+. HER2 loss or topo1mt on PD.”

Further Reading.
Source: Kohei Shitara/X